TY - JOUR
T1 - Circulating levels of endothelial progenitor cells are associated with better cognitive function in older adults with glucagon-like peptide 1 receptor agonist-treated type 2 diabetes
AU - Longo, Miriam
AU - Di Meo, Irene
AU - Caruso, Paola
AU - Muscio, Maria Francesca
AU - Scappaticcio, Lorenzo
AU - Maio, Antonietta
AU - Maiorino, Maria Ida
AU - Bellastella, Giuseppe
AU - Signoriello, Giuseppe
AU - Knop, Filip K
AU - Rizzo, Maria Rosaria
AU - Esposito, Katherine
N1 - Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
PY - 2023/6
Y1 - 2023/6
N2 - AIMS: To evaluate cognitive function in subjects with type 2 diabetes (T2D) treated with glucagon-like peptide 1 receptor agonist (GLP-1RA) plus metformin or metformin alone and its association with endothelial progenitor cells (EPCs).METHODS: Adults with T2D treated with GLP-1RA plus metformin (GLP-1RA + MET) or MET alone for at least 12 months were included. Montreal Cognitive Assessment test (MoCA), Mini-Mental State Examination (MMSE), Mini Nutritional Assessment (MNA) and disability tests were administered. Circulating levels of seven EPCs phenotypes were measured by flow cytometry.RESULTS: A total of 154 elderly patients were included, of whom 78 in GLP-1RA + MET group and 76 in MET group. The GLP-1RA + MET group showed better cognitive function as indicated by a significant higher MoCA and MMSE scores, and higher levels of CD34+ CD133+, CD133+ KDR+, and CD34+ CD133+ KDR+ as compared with MET group. The number of CD34+ CD133+ KDR+ cells was an independent predictor of higher MoCA, MMSE and MNA scores.CONCLUSIONS: People with T2D on GLP-1RA + MET treatment had better cognitive function and higher circulating levels of EPCs as compared with those on MET alone warranting further studies to understand the interrelationship between EPCs, GLP-RA treatment and cognitive health.
AB - AIMS: To evaluate cognitive function in subjects with type 2 diabetes (T2D) treated with glucagon-like peptide 1 receptor agonist (GLP-1RA) plus metformin or metformin alone and its association with endothelial progenitor cells (EPCs).METHODS: Adults with T2D treated with GLP-1RA plus metformin (GLP-1RA + MET) or MET alone for at least 12 months were included. Montreal Cognitive Assessment test (MoCA), Mini-Mental State Examination (MMSE), Mini Nutritional Assessment (MNA) and disability tests were administered. Circulating levels of seven EPCs phenotypes were measured by flow cytometry.RESULTS: A total of 154 elderly patients were included, of whom 78 in GLP-1RA + MET group and 76 in MET group. The GLP-1RA + MET group showed better cognitive function as indicated by a significant higher MoCA and MMSE scores, and higher levels of CD34+ CD133+, CD133+ KDR+, and CD34+ CD133+ KDR+ as compared with MET group. The number of CD34+ CD133+ KDR+ cells was an independent predictor of higher MoCA, MMSE and MNA scores.CONCLUSIONS: People with T2D on GLP-1RA + MET treatment had better cognitive function and higher circulating levels of EPCs as compared with those on MET alone warranting further studies to understand the interrelationship between EPCs, GLP-RA treatment and cognitive health.
KW - Humans
KW - Diabetes Mellitus, Type 2/drug therapy
KW - Endothelial Progenitor Cells
KW - Antigens, CD34
KW - Glucagon-Like Peptide 1
KW - Metformin/therapeutic use
KW - Cognition
KW - Glucagon-Like Peptide-1 Receptor/agonists
KW - Hypoglycemic Agents/therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=85156193647&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2023.110688
DO - 10.1016/j.diabres.2023.110688
M3 - Journal article
C2 - 37116797
SN - 0168-8227
VL - 200
SP - 110688
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
M1 - 110688
ER -